PACB (Pacific Biosciences of California) Debt-to-Equity : 2.03 (As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Pacific Biosciences of California Debt-to-Equity?

Pacific Biosciences of California's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $10.7 Mil. Pacific Biosciences of California's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $910.1 Mil. Pacific Biosciences of California's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $453.1 Mil. Pacific Biosciences of California's debt to equity for the quarter that ended in Sep. 2024 was 2.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Pacific Biosciences of California's Debt-to-Equity or its related term are showing as below:

PACB' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.11 Med: 0.71 Max: 3.62
Current: 2.03

During the past 13 years, the highest Debt-to-Equity Ratio of Pacific Biosciences of California was 3.62. The lowest was 0.11. And the median was 0.71.

PACB's Debt-to-Equity is ranked worse than
94.32% of 704 companies
in the Medical Devices & Instruments industry
Industry Median: 0.22 vs PACB: 2.03

Pacific Biosciences of California Debt-to-Equity Historical Data

The historical data trend for Pacific Biosciences of California's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacific Biosciences of California Debt-to-Equity Chart

Pacific Biosciences of California Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.12

0.13

1.21

1.69

1.33

Pacific Biosciences of California Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															1.23	1.33	1.44	1.88	2.03

Competitive Comparison of Pacific Biosciences of California's Debt-to-Equity

For the Medical Devices subindustry, Pacific Biosciences of California's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pacific Biosciences of California's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Pacific Biosciences of California's Debt-to-Equity falls into.

Pacific Biosciences of California Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Pacific Biosciences of California's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.081	+	923.849)	/	701.304
	=	1.33

Pacific Biosciences of California's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.675	+	910.077)	/	453.122
	=	2.03

Pacific Biosciences of California (NAS:PACB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Pacific Biosciences of California Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Pacific Biosciences of California's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Pacific Biosciences of California Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pacific Biosciences of California Inc (NAS:PACB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

P09:Germany

Address

1305 O’Brien Drive, Menlo Park, CA, USA, 94025

Website

https://www.pacb.com

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Executives

Christian O Henry	director	9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Jeff Eidel	officer: See Remarks	1305 O'BRIEN DR., MENLO PARK CA 94025
Oene Mark Van	officer: Chief Operating Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Michele Farmer	officer: Chief Accounting Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
David W Meline	director	3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Susan G. Kim	officer: Chief Financial Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
William W. Ericson	director	777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404
Peter Fromen	officer: Chief Commercial Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Hannah Valantine	director	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Michael Hunkapiller	director	400 HAMILTON AVENUE, 4TH FLOOR, PALO ALTO CA 94301
Eric Schaefer	officer: VP Chief Accounting Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Kathy Ordonez	director	3 GIRALDA FARMS, C/O QUEST DIAGNOSTICS, MADISON NJ 07940
Randall S Livingston	director
Lucy Shapiro	director	10210 GENETIC CENTER COURT, SAN DIEGO CA 92121
David Botstein	director	1380 WILLOW ROAD, PACIFIC BIOSCIENCES OF CALIFORNIA INC, MENLO PARK CA 94025